Rallybio (NASDAQ:RLYB – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Rallybio to similar companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, profitability and risk.
Profitability
This table compares Rallybio and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rallybio | -911.07% | -31.44% | -29.89% |
| Rallybio Competitors | -12,224.09% | -202.33% | -31.23% |
Volatility & Risk
Rallybio has a beta of -0.73, meaning that its stock price is 173% less volatile than the S&P 500. Comparatively, Rallybio’s peers have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Valuation & Earnings
This table compares Rallybio and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Rallybio | $860,000.00 | -$8.98 million | -4.28 |
| Rallybio Competitors | $699.91 million | $8.25 million | -18.80 |
Rallybio’s peers have higher revenue and earnings than Rallybio. Rallybio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings for Rallybio and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rallybio | 1 | 0 | 0 | 0 | 1.00 |
| Rallybio Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 126.25%. Given Rallybio’s peers stronger consensus rating and higher probable upside, analysts plainly believe Rallybio has less favorable growth aspects than its peers.
Institutional and Insider Ownership
90.3% of Rallybio shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Rallybio peers beat Rallybio on 7 of the 13 factors compared.
About Rallybio
Rallybio is a clinical-stage biotechnology company focused on developing treatments for people affected by rare and severe diseases. Founded in 2018, the company is based in New Haven, Connecticut, and has concentrated its research and development efforts on conditions with significant unmet medical needs. One of Rallybio’s investigational programs is RLYB212, an antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that can cause dangerously low platelet counts in a fetus or newborn.
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
